Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.
Nitya Raj, MD, clinical director, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the results of a phase 4 trial (NCT03289741) comparing injection site pain with octreotide long-acting release (LAR) vs lanreotide in well-differentiatedneuroendocrine tumors (NETs).
The results of this randomized, blinded trial, which were presented during the 2021 NANETS Symposium, did not demonstrate a significant difference in the patient experience regarding comfort and pain with the injection with octreotide LAR vs lanreotide, Raj says. Among patients who received octreotide LAR first, the mean injection site pain score was 2.4 compared with 1.9 in patients who received lanreotide first, Raj explains.
The difference in these pain scores was not statistically significant, Raj continues. Moreover, it is important to recognize that out of a 10-point scale, the pain experience by patients was relatively low overall, Raj concludes.